Cover Image

BRAF V600E and retinoic acid in radioiodine-refractory papillary thyroid cancer

Radioiodine refractoriness in differentiated thyroid cancer remains an unsolved therapeutic problem. Response to retinoids might depend on specific genetic markers. In this retrospective analysis, associations between BRAF V600E and clinical outcomes after redifferentiation with retinoic acid (RA) a...

Full description

Saved in:
Bibliographic Details
Main Authors: Gröner, Jan (Author) , Gelen, Debora (Author) , Herpel, Esther (Author) , Kender, Zoltán (Author) , Haufe, Sabine (Author) , Haberkorn, Uwe (Author) , Sulaj, Alba (Author) , Zemva, Johanna (Author) , Kopf, Stefan (Author) , Nawroth, Peter Paul (Author) , Brune, Maik (Author) , Rudofsky, Gottfried (Author)
Format: Article (Journal)
Language:English
Published: 2019
In: Hormone and metabolic research
Year: 2019, Volume: 51, Issue: 01, Pages: 69-75
ISSN:1439-4286
DOI:10.1055/a-0765-9078
Online Access:Verlag, Volltext: https://doi.org/10.1055/a-0765-9078
Verlag, Volltext: http://www.thieme-connect.de/DOI/DOI?10.1055/a-0765-9078
Get full text
Author Notes:Jan Benedikt Groener, Debora Gelen, Carolin Mogler, Esther Herpel, Csaba Toth, Zoltan Kender, Marco Peichl, Sabine Haufe, Uwe Haberkorn, Alba Sulaj, Johanna Zemva, Stefan Kopf, Peter Paul Nawroth, Maik Brune, Gottfried Rudofsky
Description
Summary:Radioiodine refractoriness in differentiated thyroid cancer remains an unsolved therapeutic problem. Response to retinoids might depend on specific genetic markers. In this retrospective analysis, associations between BRAF V600E and clinical outcomes after redifferentiation with retinoic acid (RA) and radioiodine therapy (RIT) were investigated. Thirteen patients with radioiodine-refractory (RAI-R) papillary thyroid cancer (PTC) were treated with 13-cis-RA followed by iodine-131 treatment at the Department of Endocrinology, Heidelberg University Hospital, Heidelberg, Germany. DNA sequencing was performed in formalin-fixed paraffin-embedded tissue. Clinical outcome parameters were tumor size, thyroglobulin, and radioiodine uptake in correlation to mutational status. Differences of each parameter were compared before and after RA/RIT. Initial response showed no difference in patients with BRAF V600E compared to patients with wild type. However, after a median follow-up of 2 and a half years, 2 out of 3 patients with BRAF V600E showed response compared to 5 out of 9 with wild type under consideration of all 3 parameters. In this small cohort, more RAI-R PTC patients with BRAF V600E receiving redifferentiation therapy showed response. Verification in a larger study population analyzing mutational status in patients with RAI-R PTC might be helpful to identify patients where redifferentiation therapy might lead to an improved outcome.
Item Description:05. November 2018 (efirst)
Gesehen am 16.05.2019
Physical Description:Online Resource
ISSN:1439-4286
DOI:10.1055/a-0765-9078

Similar Items